Dapsone human studies: what the acne and safety trials show

Last updated 2026-07-27

What do the actual human trials on dapsone show?

Two very different bodies of research exist here, and mixing them up is the single most common mistake people make when they search "dapsone studies." One line of research looks at topical dapsone gel for acne, a low-risk product applied to skin. The other looks at oral dapsone tablets, a systemic sulfone antibiotic used for leprosy, dermatitis herpetiformis, and some inflammatory conditions, with a much longer list of serious side effects. The topical acne trials are the ones most people researching "dapsone for skin" actually care about. The main Phase 3 program for dapsone gel 5% (Aczone) enrolled over 3,000 patients across two identical 12-week, randomized, double-blind, vehicle-controlled trials ^[1]. The oral studies are older and smaller by comparison. They were done for entirely different diseases, mostly leprosy and dermatitis herpetiformis, not acne. Here's the plain version: if you're asking about acne, you want the topical data. If you're asking about the antibiotic version prescribed for skin conditions like dermatitis herpetiformis or off-label inflammatory issues, you want the oral safety data, and that data comes with a hard requirement for G6PD blood testing before you ever take a pill.

How well does topical dapsone gel work for acne in clinical trials?

Topical dapsone gel 5% reduced inflammatory acne lesions by roughly 48% versus about 43% for vehicle gel at week 12 in the original FDA registration trials, a modest but statistically significant edge ^[1]. A separate, often-cited trial in the Journal of Drugs in Dermatology found similar results, with dapsone gel 5% producing significantly greater reduction in inflammatory lesion counts than vehicle by week 12 ^[2]. The newer 7.5% formulation, approved in 2016, was studied in two 12-week trials involving more than 4,000 patients combined, and showed roughly 48.9% and 50.6% mean reductions in inflammatory lesions at the two trial sites, compared to vehicle gel reductions of about 43.2% and 44.4% ^[3]. That's not a dramatic gap. It's a real but incremental improvement over placebo gel, which itself does something (vehicle effects in acne trials are notoriously non-trivial because the act of washing and applying anything on a regular schedule helps somewhat). What the numbers don't tell you: dapsone gel works better on inflammatory lesions (papules, pustules) than on comedones (blackheads, whiteheads). If your acne is mostly non-inflammatory, don't expect much from it. It's also FDA-approved as monotherapy, but many dermatologists pair it with a retinoid or benzoyl peroxide, since combination regimens dominate real-world acne treatment and weren't isolated as a separate arm in most of the main trials. | Trial | Formulation | Duration | Inflammatory lesion reduction (drug vs vehicle) |

Is topical dapsone safe for long-term use, and does it need G6PD testing?

No. Topical dapsone gel does not require G6PD testing, and that's one of the biggest practical differences between the topical and oral forms. FDA labeling for dapsone gel notes that hematologic effects seen with oral dapsone, hemolysis and methemoglobinemia, were not observed at clinically relevant rates in G6PD-deficient patients using the topical gel, because systemic absorption is minimal ^[4]. A study specifically looking at G6PD-deficient patients using topical dapsone gel 5% found no clinically significant changes in hemoglobin or evidence of hemolytic anemia over 12 weeks of use ^[5]. That's reassuring, but it's also a narrow, short-duration dataset, not a lifetime-of-use guarantee, and dermatologists still tend to mention G6PD status if a patient already knows it, mostly out of caution rather than strict necessity. The most common side effects in the topical trials were mild: dryness, redness, and some peeling at the application site, alongside a curious cosmetic quirk. Combining dapsone gel with benzoyl peroxide can cause temporary yellow-orange skin discoloration, an interaction the FDA label specifically calls out ^[4]. It washes off and isn't dangerous, but it surprises people who weren't warned.

What do oral dapsone human studies show for skin conditions?

Oral dapsone has a genuinely different evidence base, built around leprosy treatment since the 1940s-50s and dermatitis herpetiformis since the 1950s, not acne. The WHO's multidrug therapy regimen for leprosy has included dapsone as a core component for decades, and its efficacy against Mycobacterium leprae in that context is well established ^[6]. For dermatitis herpetiformis, the itchy, blistering skin condition linked to celiac disease, oral dapsone (typically 50-200mg daily, sometimes less) produces rapid symptom relief, often within 1-3 days, according to clinical reviews of its use in that condition ^[7]. That fast response is actually part of how dermatologists sometimes use dapsone as a diagnostic tool, since few other treatments work that quickly on DH-related blistering. What's missing: large, modern randomized trials of oral dapsone specifically for acne. It isn't FDA-approved for oral acne treatment, and using it that way would mean taking on the full oral side effect profile for a condition where the topical form already exists and is dramatically safer. Nobody running a legitimate derm practice reaches for oral dapsone as a first-line acne drug.

Why does oral dapsone require G6PD testing before you start it?

Because oral dapsone can trigger severe, sometimes life-threatening hemolytic anemia in people with G6PD deficiency, an enzyme deficiency that affects an estimated 400 million people worldwide and roughly 1 in 10 Black American men in the U.S. . G6PD deficiency makes red blood cells vulnerable to oxidative stress, and dapsone is a strong oxidant drug. The FDA-approved oral dapsone label is explicit: "Hemolysis, sometimes severe, may occur in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency" and recommends G6PD testing before starting therapy . This isn't a hedge or a defensive-medicine formality. It's a documented, dose-related risk with real cases of severe hemolysis and even death reported in G6PD-deficient patients on oral dapsone therapy . Beyond hemolysis, oral dapsone carries a list of other serious risks that don't apply to the topical gel: methemoglobinemia (reduced oxygen-carrying capacity of blood, causing fatigue, cyanosis, shortness of breath), agranulocytosis (dangerous drop in white blood cells, more common in the first 12 weeks of treatment), and dapsone hypersensitivity syndrome, a rare but severe reaction involving fever, rash, and organ involvement that can be fatal in a meaningful fraction of cases . This is exactly why oral dapsone is a prescription antibiotic managed with baseline and follow-up blood work, not a casual acne fix, and why conflating it with the topical gel is dangerous.

How is dapsone hypersensitivity syndrome different from a normal drug rash?

Dapsone hypersensitivity syndrome (DHS) is a rare, severe, delayed reaction to oral dapsone that typically appears 2 to 6 weeks after starting therapy, featuring fever, widespread rash, swollen lymph nodes, and internal organ involvement (commonly liver, sometimes lung or kidney). It's not a typical allergic rash; it's closer to a systemic inflammatory reaction, and it belongs to the broader family of drug reactions clinicians call DRESS (drug reaction with eosinophilia and systemic symptoms). Reported mortality for DHS in published case series ranges roughly from 9.9% to as high as 12%, depending on the cohort and how aggressively it's caught and treated . That's a sobering number for a drug reaction, and it's part of why oral dapsone prescribing includes close early monitoring, not a set-it-and-forget-it 90-day script. Early signs, fever and rash appearing weeks (not days) after starting oral dapsone, are the trigger for stopping the drug and seeking care immediately. This risk profile simply does not exist with topical dapsone gel, because the systemic drug exposure that drives DHS isn't there in meaningful amounts.

Does dapsone gel interact with benzoyl peroxide or other acne treatments?

Yes, mildly and cosmetically, not dangerously. The interaction that shows up most often in the trial data and product labeling is a temporary yellow-orange skin and facial hair discoloration when dapsone gel 5% is used together with benzoyl peroxide, noted directly in the FDA prescribing information ^[4]. It's not a safety issue. It's a staining effect that resolves with washing and doesn't damage skin, but it catches people off guard if their dermatologist didn't mention it. If you're combining dapsone gel with benzoyl peroxide products, applying them at different times of day (one in the morning, one at night) is the practical workaround most dermatologists suggest, though this isn't something the trials tested head-to-head. Combining dapsone gel with topical retinoids (tretinoin, adapalene) doesn't carry the same discoloration issue and is common in real-world acne regimens, even though the original approval trials studied dapsone gel largely as monotherapy against vehicle.

How fast does dapsone gel start working for acne, and how long until full results?

Most of the visible lesion reduction in the trials built up steadily over 12 weeks, with statistically significant separation from vehicle gel typically emerging by week 4 to 8 and continuing to improve through week 12 ^[1][3]. Don't expect a dramatic two-week transformation; this is a slow-burn topical, similar in pace to most other topical acne treatments (benzoyl peroxide, topical retinoids). A fair way to set expectations: judge dapsone gel at the 8 to 12 week mark, not at 2 weeks. If you see zero change by 12 weeks of consistent twice-daily use, that's a reasonable point to talk to a prescriber about switching or adding something else, rather than pushing on for months longer on faith. For anyone tracking their own regimen closely, understanding the drug's clearance and reapplication schedule matters too; the half life of topical versus oral dapsone differs substantially and affects how forgiving missed doses are.

What's the real difference between Aczone 5% and Aczone 7.5%?

The main practical difference is dosing frequency: the original 5% gel is applied twice daily, while the 7.5% formulation, approved by the FDA in 2016, is applied once daily ^[3]. Efficacy between the two was broadly similar in their respective trials, with inflammatory lesion reductions in the high-40s to low-50s percentage range for both strengths versus vehicle ^[1][3]. The once-daily 7.5% version exists mainly for adherence, since real-world data on topical acne treatments consistently shows that patients skip the second daily application far more than the first. If cost and insurance coverage are similar, most dermatologists now default to the 7.5% for that reason alone, not because it's dramatically more effective on paper. Neither strength requires G6PD testing, and neither carries the systemic hemolysis or agranulocytosis risks tied to oral dapsone, because topical absorption stays low enough that blood levels remain far below the threshold associated with those effects ^[4][5].

What monitoring does oral dapsone require that topical dapsone doesn't?

Oral dapsone prescribing typically includes a baseline G6PD test, baseline complete blood count (CBC), and then repeat CBCs during the early months of treatment, often weekly or biweekly for the first month, then tapering to monthly, because agranulocytosis risk is highest in the first 12 weeks . Liver function tests are also commonly checked given rare reports of hepatotoxicity. Topical dapsone gel requires none of this. There's no standard requirement for baseline bloodwork before starting the gel, and the FDA label doesn't call for routine CBC monitoring during topical treatment, a direct reflection of how much lower the systemic exposure is ^[4]. If your prescriber has recommended oral dapsone for a skin condition, ask directly what monitoring schedule they're using and why, since practices vary by indication (leprosy protocols differ somewhat from dermatitis herpetiformis protocols) ^[6][7]. If you're instead using or considering the topical gel for acne, Dapsone Rx works with patients through a provider-reviewed process, and prescriptions are filled through a licensed fulfilling pharmacy partner rather than any compounding done by the brand itself.

Where can I find dapsone prescribed for acne, and what should I ask my provider?

If your provider recommends dapsone gel for acne, reasonable questions include: which strength (5% vs 7.5%), what to expect by week 4 versus week 12, whether to pair it with benzoyl peroxide or a retinoid, and how to handle the yellow-tinge interaction if you do combine it with benzoyl peroxide ^[1][3][4]. If, instead, oral dapsone comes up for a skin condition (dermatitis herpetiformis being the most common legitimate dermatologic indication), the questions shift entirely: has G6PD testing been done, what's the CBC monitoring schedule, and what symptoms (fever, rash, unusual fatigue, shortness of breath) should prompt an immediate call rather than waiting for the next visit . For people managing dosing logistics day to day, whether topical routine or an oral regimen under supervision, practical resources like a dosage calculator, guidance on storage and shelf life, and whether the product needs refrigeration are worth reviewing alongside anything your prescriber tells you directly.

Frequently asked questions

Is dapsone gel the same drug as oral dapsone?

Chemically, yes, both contain dapsone. Practically, they behave very differently. Topical gel has minimal systemic absorption and a strong safety record for acne without G6PD testing, while oral dapsone is absorbed into the bloodstream fully and carries risks of hemolysis, methemoglobinemia, and hypersensitivity syndrome that require G6PD screening and blood monitoring ^[4][9].

Do I need a G6PD test before using dapsone gel for acne?

No. FDA labeling and dedicated studies in G6PD-deficient patients found no clinically significant hemolysis with topical dapsone gel over 12 weeks of use, because systemic absorption stays low ^[4][5]. G6PD testing is a requirement for oral dapsone, not the topical gel.

How much do inflammatory acne lesions improve with dapsone gel?

Across the FDA trials, dapsone gel 5% and 7.5% reduced inflammatory lesions by roughly 48% to 51% over 12 weeks, compared to about 43% to 44% with vehicle gel alone, a modest but statistically significant advantage ^[1][3].

What is dapsone hypersensitivity syndrome and how common is it?

It's a rare, delayed severe reaction to oral dapsone appearing 2 to 6 weeks after starting treatment, with fever, rash, and organ involvement. Published mortality estimates in case series run roughly 9.9% to 12%, which is why early symptoms prompt immediate medical attention ^[10].

Can dapsone gel be used with benzoyl peroxide?

Yes, but the combination can cause temporary yellow-orange discoloration of skin and facial hair, noted directly in FDA labeling. It's cosmetic, not dangerous, and washes off; many people apply the two products at different times of day to avoid it ^[4].

Is oral dapsone approved for acne treatment?

No. Oral dapsone isn't FDA-approved for acne. It's approved for leprosy and dermatitis herpetiformis, and used off-label for certain other inflammatory skin conditions, but not as an acne treatment, where the topical gel form is the approved and far safer option ^[6][7][9].

How long does it take to see results from topical dapsone gel?

Most trial data shows measurable, statistically significant improvement over vehicle gel emerging by weeks 4 to 8, with continued improvement through the 12-week trial endpoint. It's a gradual effect, not a quick fix, similar in pace to other topical acne treatments ^[1][3].

What blood tests are needed before starting oral dapsone?

Standard practice includes a baseline G6PD test and baseline complete blood count, followed by repeat CBCs during early treatment (often weekly or biweekly for the first month) since agranulocytosis risk peaks in the first 12 weeks of therapy ^[9].

Who is most at risk for G6PD-related complications from dapsone?

G6PD deficiency affects an estimated 400 million people globally and is notably more common in people of African, Mediterranean, and Southeast Asian descent, including roughly 1 in 10 Black American men, making pre-treatment screening standard practice before oral dapsone ^[8].

Does topical dapsone gel cause methemoglobinemia like the oral form?

Clinically significant methemoglobinemia is a documented risk of oral dapsone, not the topical gel, due to the difference in systemic drug exposure. FDA trial data on the gel did not identify this as a meaningful risk at typical topical dosing ^[4].

What's the difference between Aczone 5% and 7.5% gel?

5% gel is applied twice daily; 7.5% gel, approved in 2016, is applied once daily with similar efficacy in its trials. The main advantage of 7.5% is better adherence from simpler dosing, not a dramatically stronger effect ^[3].

Can dapsone gel be used for non-inflammatory acne like blackheads?

It's less effective there. Trial data shows dapsone gel works better on inflammatory lesions (papules and pustules) than on comedones. If non-inflammatory acne is the main issue, a retinoid is typically a better first choice ^[1][2].

Sources

1. Draelos ZD et al., Journal of Drugs in Dermatology, dapsone gel 5% acne trial: Significant reduction in inflammatory acne lesion counts with dapsone gel 5% versus vehicle at 12 weeks
2. FDA, Aczone (dapsone) Gel 7.5% Prescribing Information: Phase 3 trial results for dapsone gel 7.5% once-daily formulation approved in 2016
3. Piette WW et al., Journal of the American Academy of Dermatology, dapsone gel G6PD study: No clinically significant hemolysis or hemoglobin change in G6PD-deficient patients using topical dapsone gel 5% over 12 weeks
4. World Health Organization, Guidelines for the Diagnosis, Treatment and Prevention of Leprosy: Dapsone as a core component of multidrug therapy for leprosy
5. National Institute of Diabetes and Digestive and Kidney Diseases / clinical review on dermatitis herpetiformis treatment: Oral dapsone produces rapid symptom relief in dermatitis herpetiformis, often within days
6. CDC, Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: G6PD deficiency prevalence estimates including among Black American men
7. Lorenz M et al., dapsone hypersensitivity syndrome case series review, published dermatology literature: Reported mortality range for dapsone hypersensitivity syndrome cases